Thyroglobulin Test at 3 Weeks after Surgery in Well-Differentiated Thyroid Cancer and its Predictive Value: The Role of Endocrine–Metabolic Status

References

• Ito Y , NikiforovYE, SchlumbergerM, VigneriR. Increasing incidence of thyroid cancer: controversies explored. Nat. Rev. Endocrinol.9(3), 178–184 (2013).
   PubMed Web of Science ®Google Scholar
• Hoang JK , Roy ChoudhuryK, EastwoodJDet al. An exponential growth in incidence of thyroid cancer: trends and impact of CT imaging. Am J Neuroradiol. (doi: 10.3174/ajnr.A37432013) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Sosa JA , HannaJW, RobinsonKA, LanmanRB. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery154(6), 1420–1426, discussion 1426–1427 (2013).
   PubMed Web of Science ®Google Scholar
• Hay ID , ThompsonGB, GrantCSet al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg.26(8), 879–885 (2002).
   PubMed Web of Science ®Google Scholar
• Pathak KA , MazuratA, LambertP, KlonischT, NasonRW. Prognostic nomograms to predict oncological outcome of thyroid cancers. J. Clin. Endocrinol. Metab.98(12), 4768–4775 (2013).
   PubMed Web of Science ®Google Scholar
• Guarino E , TarantiniB, PilliTet al. Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer. Thyroid15(9), 1041–1045 (2005).
   PubMed Web of Science ®Google Scholar
• Giovanella L . Thyroglobulin measurement in differentiated thyroid carcinoma measurement. Expert Rev. Endocrinol. Metab.3(2), 117–125 (2008).
   PubMedGoogle Scholar
• Rosario PW , Mineiro FilhoAF, PratesBS, SilvaLC, CalsolariMR. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid22(11), 1140–1143 (2012).
   PubMed Web of Science ®Google Scholar
• Webb RC , HowardRS, StojadinovicAet al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J. Clin. Endocr. Metab.97(8), 2754–2763 (2012).
   PubMed Web of Science ®Google Scholar
• Giovanella L , CerianiL, GhelfoA, KellerF. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin. Chem. Lab. Med.43(8), 843–847 (2005).
   PubMed Web of Science ®Google Scholar
• Lima N , CavaliereH, TomimoriE, KnobelM, Medeiros-NetoG. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J. Endocrinol. Invest.25(2), 110–115 (2002).
   PubMed Web of Science ®Google Scholar
• Ronga G , FilesiM, VentroniG, VestriAR, SignoreA. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur. J. Nucl. Med.26(11), 1448–1452 (1999).
   PubMedGoogle Scholar
• Grünwald F , MenzelC, FimmersR, ZamoraPO, BiersackHJ. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J. Nucl. Med.37(12), 1962–1964 (1996).
   PubMed Web of Science ®Google Scholar
• Webb RC , HowardRS, StojadinovicAet al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J. Clin. Endocr. Metab.97(8), 2754–2763 (2012).
   PubMed Web of Science ®Google Scholar
• Golger A , FridmanTR, EskiS, WitterickIJ, FreemanJL, WalfishPG. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J. Endocrinol. Invest.26(10), 1023–1031 (2003).
   PubMed Web of Science ®Google Scholar
• Bombardieri E , SeregniE, VillanoC, AlibertiG, MattavelliF. Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer. Tumori89(5), 533–536 (2003).
   PubMed Web of Science ®Google Scholar
• Nascimento C , BorgetI, TroalenFet al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur. J. Endocrinol.169(5), 689–693 (2013).
   PubMed Web of Science ®Google Scholar
• Schlumberger M , BorgetI, NascimentoC, BrassardM, LeboulleuxS. Treatment and follow-up of low-risk patients with thyroid cancer. Nat. Rev. Endocrinol.7(10), 625–628 (2011).
   PubMed Web of Science ®Google Scholar
• Trimboli P , La TorreD, CerianiLet al. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients? Horm. Metab. Res. 45(9), 664–668 (2013).
   PubMed Web of Science ®Google Scholar
• Hay ID . Management of patients with low-risk papillary thyroid carcinoma. Endocr. Pract..13(5), 521–533 (2007).
   PubMedGoogle Scholar
• Sitges-Serra A . Low-risk papillary thyroid cancer: times are changing. Expert Rev. Endocrinol. Metab.9(1), 9–18 (2014).
   PubMedGoogle Scholar
• Pazaitou-Panayiotou K , PolyzosSA, MantzorosCS. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes. Rev. doi: 10.1111/obr.12070 (2013) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Fröhlich E , WahlR. Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?Diabetes Obes. Metab.14(3), 204–213 (2012).
   PubMed Web of Science ®Google Scholar
• Rezzónico JN , RezzónicoM, PusiolE, PitoiaF, NiepomniszczeH. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab. Syndr. Relat. Disord.7(4), 375–380 (2009).
   PubMed Web of Science ®Google Scholar
• Fiore E , VittiP. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J. Clin. Endocrinol. Metab.97(4), 1134–1145 (2012).
   PubMed Web of Science ®Google Scholar
• Middendorp M , GrünwaldF. Update on recent developments in the therapy of differentiated thyroid cancer. Semin. Nucl. Med.40(2), 145–152 (2010).
   PubMed Web of Science ®Google Scholar
• Suh YJ , SonEJ, MoonHJ, KimEK, HanKH, KwakJY. Utility of thyroglobulin measurements in fine-needle aspirates of space occupying lesions in the thyroid bed after thyroid cancer operations. Thyroid23(3), 280–288 (2013).
   PubMed Web of Science ®Google Scholar
• Balkan F , OnalED, UsluogullariAet al. Is there any association between insulin resistance and thyroid cancer?: a case control study. Endocrine45(1), 55–60 (2014).
   PubMed Web of Science ®Google Scholar
• Paes JE , HuaK, NagyR, KloosRT, JarjouraD, RingelMD. The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J. Clin. Endocrinol. Metab.95(9), 4244–4250 (2010).
   PubMed Web of Science ®Google Scholar
• Biondi B , CooperDS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid20(2), 135–146 (2010).
   PubMed Web of Science ®Google Scholar
• Salpeter SR , BuckleyNS, KahnJA, SalpeterEE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med.121(2), 149–157 (2008).
   PubMed Web of Science ®Google Scholar
• Berstein LM . Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany)4(5), 320–329 (2012).
   PubMedGoogle Scholar
• Lupoli R1 , Di MinnoA, TortoraA, AmbrosinoP, LupoliGA, Di MinnoMN. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J. Clin. Endocrinol. Metab.99(1), E143–E148 (2014).
   PubMed Web of Science ®Google Scholar
• Chen G , XuS, RenkoK, DerwahlM. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab.97(4), E510–E520 (2012).
   PubMed Web of Science ®Google Scholar
• Fernandez IJ , PiccinO, SciasciaSet al. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol. Head Neck Surg.148(6), 919–25 (2013).
   PubMedGoogle Scholar
• Miyauchi A , KudoT, MiyaAet al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid21(7), 707–716 (2011).
   PubMed Web of Science ®Google Scholar